Response to Denosumab Treatment for 2 Years in an Adolescent With Osteoradionecrosis. (21st May 2015)

• Record Type: Journal Article
• Authors: Vázquez, M Angeles; Pérez‐Temprano, Ramón; Montoya, M José; Giner, Mercè; Carpio, José; Pérez‐Cano, Ramon
• Is Part Of: Journal of bone and mineral research. Volume 30:Number 10(2015:Oct.)
• Page Start: 1790
• Page End: 1796
• Publication Date: 2015-05-21
• Subjects: OSTEORADIONECROSIS -- BONE MINERAL DENSITY -- PATHOLOGICAL FRACTURES -- ADOLESCENT -- DENOSUMAB; Bones -- Metabolism -- Periodicals; Mineral metabolism -- Periodicals; 612.392
• DOI: 10.1002/jbmr.2519
• Languages: English
• ISSNs: 0884-0431

Abstract

ABSTRACT: Radiotherapy, an essential component of cancer treatment, is not without risk to bone, particularly to the immature or growing skeleton. Known side effects range from post‐radiation osteitis to osteoradionecrosis. We report the case of a 14‐year‐old male patient undergoing denosumab treatment, a new antiresorptive agent, for osteoradionecrosis. The patient exhibited fractures and associated pain and functional limitations secondary to radiation for the treatment of an embryonal rhabdomyosarcoma of prostate grade III administered at age 5 years. After treatment with denosumab, the pain disappeared, bone remodeling markers dramatically declined, bone mass increased, and pathological bone scan findings resolved without adverse effects or new fractures. © 2015 American Society for Bone and Mineral Research.